Patents Assigned to Xoma Corporation
  • Patent number: 5945399
    Abstract: Methods and materials for the treatment of humans suffering from hemorrhage due to trauma are provided, in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: May 23, 1997
    Date of Patent: August 31, 1999
    Assignee: XOMA Corporation
    Inventors: Patrick J. Scannon, Nancy Wedel
  • Patent number: 5935930
    Abstract: Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: April 20, 1998
    Date of Patent: August 10, 1999
    Assignee: Xoma Corporation
    Inventors: Mark L. White, William Steve Ammons
  • Patent number: 5932544
    Abstract: Bactericidal/permeability increasing protein (BPI) and biologically active fragments, analogs and variants thereof are solubilized by lipid carriers including phospholipids, liposomes and nonionic detergents and stabilized against particle formation by poloxamer surfactants.
    Type: Grant
    Filed: May 31, 1994
    Date of Patent: August 3, 1999
    Assignee: XOMA Corporation
    Inventor: Lynn S. Grinna
  • Patent number: 5912228
    Abstract: Improved therapeutic compositions having enhanced anti-microbial activity comprising a bactericidal/permeability-increasing (BPI) protein product and an bactericidal-activity enhancing polyoxyethylene block copolymer surfactant (poloxamer) surfactant or a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant, optionally with EDTA, and methods for treating bacterial infection by administering such compositions, alone or concurrently with antibiotics.
    Type: Grant
    Filed: January 12, 1996
    Date of Patent: June 15, 1999
    Assignee: XOMA Corporation
    Inventor: Lewis H. Lambert, Jr.
  • Patent number: 5891618
    Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: April 6, 1999
    Assignee: XOMA Corporation
    Inventors: Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-kuen Ma
  • Patent number: 5888973
    Abstract: The present invention relates to methods for treating chlamydial infection comprising administering to a subject suffering from a chlamydial infection a bactericidal/permeability-inducing (BPI) protein product.
    Type: Grant
    Filed: August 9, 1996
    Date of Patent: March 30, 1999
    Assignee: XOMA Corporation
    Inventor: Lewis H. Lambert, Jr.
  • Patent number: 5869619
    Abstract: Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: February 9, 1999
    Assignee: XOMA Corporation
    Inventor: Gary M. Studnicka
  • Patent number: 5858974
    Abstract: The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino aids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides.
    Type: Grant
    Filed: March 21, 1996
    Date of Patent: January 12, 1999
    Assignee: XOMA Corporation
    Inventors: Roger G. Little, II, Edward Lim, Mitchell B. Fadem
  • Patent number: 5856302
    Abstract: Improved therapeutic compositions, methods and uses of bactericidal/permeability-increasing protein (BPI) products involve use of dimeric forms of BPI protein product monomers characterized by enhanced in vivo biological activity. Preferred formulations include 50 percent or more by weight dimeric product and preferred therapeutic uses include endotoxin neutralization and heparin neutralization.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: January 5, 1999
    Assignee: XOMA Corporation
    Inventors: William Steve Ammons, Roger G. Little
  • Patent number: 5856438
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 5, 1999
    Assignee: XOMA Corporation
    Inventor: Roger G. Little, II
  • Patent number: 5854214
    Abstract: The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 29, 1998
    Assignee: XOMA Corporation
    Inventor: Roger G. Little, II
  • Patent number: 5851802
    Abstract: The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: December 22, 1998
    Assignee: Xoma Corporation
    Inventor: Marc D. Better
  • Patent number: 5846818
    Abstract: The invention is directed to the pectate lyase B secretion signal and its use to express operably linked sequences in bacterial hosts.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 8, 1998
    Assignee: XOMA Corporation
    Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horowitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
  • Patent number: 5843685
    Abstract: The invention is directed to a chimeric immunoglobulin that recognizes the human tumor antigen bound by antibody ING-1, its production, and use.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Arnold H. Horwitz, Randy R. Robinson, Shau-Ping Lei, Changtung Paul Chang
  • Patent number: 5837491
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: May 13, 1996
    Date of Patent: November 17, 1998
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
  • Patent number: 5837678
    Abstract: The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 17, 1998
    Assignee: XOMA Corporation
    Inventor: Roger G. Little, II
  • Patent number: 5827816
    Abstract: Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and stable homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and its sequelae.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 27, 1998
    Assignee: Xoma Corporation
    Inventors: Georgia Theofan, Arnold Horwitz, David Burke, Manik Baltaian, Lynn Grinna
  • Patent number: 5821123
    Abstract: Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 13, 1998
    Assignee: XOMA Corporation
    Inventor: Gary M. Studnicka
  • Patent number: 5821064
    Abstract: The present invention provides a method for quantifying the presence of extracellular BPI in body fluids including blood in a subject comprising conducting a BPI immunoassay on body fluid sample obtained from said subject.
    Type: Grant
    Filed: September 22, 1994
    Date of Patent: October 13, 1998
    Assignee: XOMA Corporation
    Inventors: Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-kuen Ma
  • Patent number: 5807818
    Abstract: The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: September 15, 1998
    Assignee: Xoma Corporation
    Inventor: Roger G. Little, II